Albany International

Management emphasizes balanced allocation: organic investment in core technologies and facilities, a steady dividend, and opportunistic buybacks.

In 2025 the company repurchased roughly $186 million of shares and ended the year with $76.7 million remaining under the authorization as of June 30, 2026. Capex was about $71.5 million in 2025 and $21.2 million in H1‑2026, while R&D remains consistently funded.

Strategically, the 2023 acquisition of Heimbach expanded MC scale and reach, and the 2026 decision to amend CH‑53K terms and retain the Salt Lake City facility suggests a disciplined willingness to restructure underperforming programs rather than pursue value‑destructive exits. Dilution from SBC appears manageable.

Overall, execution is solid though 2025 buybacks occurred amid subsequent earnings volatility.